Absci ABSI
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Absci (ABSI)
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Key Insights
Critical company metrics and information
Latest Closing Price
$3.12Market Cap
$358.35 MillionPrice-Earnings Ratio
-3.35Total Outstanding Shares
114.86 Million SharesTotal Employees
156Dividend
No dividendIPO Date
July 22, 2021SIC Description
Services-commercial Physical & Biological ResearchPrimary Exchange
NASDAQType
Common StockHeadquarters
18105 se mill plain blvd, Vancouver, WA, 98683Homepage
https://www.absci.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-70.36 Million |
| Net Cash Flow, Continuing | $-31.72 Million |
| Net Cash Flow From Operating Activities | $-70.36 Million |
| Net Cash Flow From Investing Activities, Continuing | $-41.66 Million |
| Net Cash Flow From Financing Activities, Continuing | $80.31 Million |
| Net Cash Flow From Investing Activities | $-41.66 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Diluted Earnings Per Share | $-0.93 |
| Diluted Average Shares | $108.85 Million |
| Nonoperating Income/Loss | $6.28 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-97.67 Million |
| Selling, General, and Administrative Expenses | $36.67 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-97.36 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-97.36 Million |
| Other Comprehensive Income/Loss | $-97.36 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Liabilities | $33.90 Million |
| Other Current Liabilities | $25.02 Million |
| Noncurrent Liabilities | $7.21 Million |
| Equity | $201.34 Million |
| Liabilities And Equity | $235.23 Million |
| Equity Attributable To Parent | $201.34 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ABSI from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.